Ennio Giulio Favalli
YOU?
Author Swipe
View article: The Impact of Sex on the Pattern and Clinical Response of Early Psoriatic Arthritis: Real-life Data from the Italian Prospective SIRENA Study
The Impact of Sex on the Pattern and Clinical Response of Early Psoriatic Arthritis: Real-life Data from the Italian Prospective SIRENA Study Open
View article: Bimekizumab Maintained Efficacy Responses in Patients with Active Psoriatic Arthritis: Up to 2-Year Results from Two Phase 3 Studies
Bimekizumab Maintained Efficacy Responses in Patients with Active Psoriatic Arthritis: Up to 2-Year Results from Two Phase 3 Studies Open
Objectives To report the proportion of Week (Wk) 16 responders maintaining their response in joint, skin, and composite efficacy outcomes up to 2 years in bimekizumab (BKZ)-treated patients (pts) with psoriatic arthritis (PsA). Methods Two…
View article: POS0479 Steroid-sparing effect of Janus kinase inhibitors compared to TNF inhibitors in rheumatoid arthritis: preliminary analysis from a single-center Italian cohort
POS0479 Steroid-sparing effect of Janus kinase inhibitors compared to TNF inhibitors in rheumatoid arthritis: preliminary analysis from a single-center Italian cohort Open
View article: ABS0687 IMPACT OF CDAI-REMISSION ON CV RISK ESTIMATION OF RA PATIENTS: INSIGHTS FROM THE CORDIS STUDY GROUP OF THE ITALIAN SOCIETY FOR RHEUMATOLOGY
ABS0687 IMPACT OF CDAI-REMISSION ON CV RISK ESTIMATION OF RA PATIENTS: INSIGHTS FROM THE CORDIS STUDY GROUP OF THE ITALIAN SOCIETY FOR RHEUMATOLOGY Open
View article: ABS0627 WILLINGNESS OF PSORIATIC ARTHRITIS PATIENTS TO PARTICIPATE IN PHARMACOLOGICAL AND NUTRITIONAL CLINICAL TRIALS: A CROSS-SECTIONAL SURVEY
ABS0627 WILLINGNESS OF PSORIATIC ARTHRITIS PATIENTS TO PARTICIPATE IN PHARMACOLOGICAL AND NUTRITIONAL CLINICAL TRIALS: A CROSS-SECTIONAL SURVEY Open
View article: ABS0929 THE 1-YEAR IMPACT OF THE APPLICATION OF EMA RECOMMENDATIONS ON THE MAINTENANCE OF CLINICAL RESPONSE IN A REAL-LIFE COHORT OF RHEUMATOID ARTHRITIS PATIENTS TREATED WITH JAK INHIBITORS
ABS0929 THE 1-YEAR IMPACT OF THE APPLICATION OF EMA RECOMMENDATIONS ON THE MAINTENANCE OF CLINICAL RESPONSE IN A REAL-LIFE COHORT OF RHEUMATOID ARTHRITIS PATIENTS TREATED WITH JAK INHIBITORS Open
View article: Whole‐Blood <scp>RNA</scp> Sequencing Profiling of Patients With Rheumatoid Arthritis Treated With Tofacitinib
Whole‐Blood <span>RNA</span> Sequencing Profiling of Patients With Rheumatoid Arthritis Treated With Tofacitinib Open
Objective Patients with rheumatoid arthritis (RA) often fail to respond to therapies, including JAK inhibitors (JAKi), and treatment allocation is made via a trial‐and‐error strategy. A comprehensive analysis of responses to JAKi, includin…
View article: Expanding the expanded risk score to psoriatic arthritis: any port in a storm
Expanding the expanded risk score to psoriatic arthritis: any port in a storm Open
View article: Multidisciplinary consensus on the diagnosis and management of patients with atypical Hemolytic Uremic Syndrome (complement-mediated TMA): Recommendations from Italian scientific societies, patient associations and regulators
Multidisciplinary consensus on the diagnosis and management of patients with atypical Hemolytic Uremic Syndrome (complement-mediated TMA): Recommendations from Italian scientific societies, patient associations and regulators Open
Atypical Hemolytic Uremic Syndrome (aHUS) is a severe, systemic, rare disease (RD) that can occur in people of all ages, and is associated with high rates of morbidity and mortality. Because the management of patients with aHUS can be diff…
View article: P171 Bimekizumab maintained efficacy responses in patients with active psoriatic arthritis: up to 2-year results from two Phase 3 studies
P171 Bimekizumab maintained efficacy responses in patients with active psoriatic arthritis: up to 2-year results from two Phase 3 studies Open
Background/Aims Bimekizumab (BKZ) has demonstrated clinically meaningful improvements in efficacy outcomes to Week (Wk)16, that were sustained to Wk52, in psoriatic arthritis (PsA) patients. We report proportions of Wk16 responders maintai…
View article: Efficacy and retention rate of secukinumab in psoriatic arthritis across different clinical phenotypes: insights from the Italian GISEA Registry
Efficacy and retention rate of secukinumab in psoriatic arthritis across different clinical phenotypes: insights from the Italian GISEA Registry Open
Background: Randomized clinical trials have demonstrated the efficacy of secukinumab (SECU) in reducing disease activity in psoriatic arthritis (PsA), while real-world studies prove a broader perspective on SECU’s usefulness in everyday cl…
View article: Spondyloarthritis and Risk of Malignancy: A Narrative Review on a Still Controversial Issue
Spondyloarthritis and Risk of Malignancy: A Narrative Review on a Still Controversial Issue Open
View article: Difficult-to-treat psoriatic arthritis: refining the definition using a statistical model in a real-life cohort
Difficult-to-treat psoriatic arthritis: refining the definition using a statistical model in a real-life cohort Open
Objectives The study aims to evaluate the applicability of the D2T psoriatic arthritis (PsA) definition, adapted from rheumatoid arthritis, within a single-center observational cohort of PsA patients treated with b/tsDMARDs. In addition, w…
View article: The holistic management of peripheral spondyloarthritis: focus on articular involvement in patients with inflammatory bowel disease
The holistic management of peripheral spondyloarthritis: focus on articular involvement in patients with inflammatory bowel disease Open
Objective. To provide a comprehensive overview of peripheral spondyloarthritis (pSpA), focusing specifically on its occurrence and management in patients with inflammatory bowel disease (IBD). Methods. An exhaustive literature search was c…
View article: Truth unveiled by time and the marbled definition of D2T-RA: retrospective analysis on the persistence of the difficult-to-treat status among refractory RA patients
Truth unveiled by time and the marbled definition of D2T-RA: retrospective analysis on the persistence of the difficult-to-treat status among refractory RA patients Open
Background The current EULAR definition of difficult-to-treat rheumatoid arthritis (D2T-RA) identifies patients with active disease refractory to multiple treatments at a single time point, without considering the persistence of this condi…
View article: Barriers to, Facilitators of, and Interventions to Support Treat‐to‐Target Implementation in Rheumatoid Arthritis: A Systematic Review
Barriers to, Facilitators of, and Interventions to Support Treat‐to‐Target Implementation in Rheumatoid Arthritis: A Systematic Review Open
Objective Treat‐to‐target is recommended in the management of rheumatoid arthritis (RA) but its implementation is suboptimal. We aimed to identify interventional strategies targeted at improving treat‐to‐target implementation in RA by syst…
View article: Biologics or Janus Kinase Inhibitors in Rheumatoid Arthritis Patients Who are Insufficient Responders to Conventional Anti-Rheumatic Drugs
Biologics or Janus Kinase Inhibitors in Rheumatoid Arthritis Patients Who are Insufficient Responders to Conventional Anti-Rheumatic Drugs Open
Rheumatoid arthritis (RA) is a chronic immune-mediated inflammatory disease which can induce progressive disability if not properly treated early. Over the last 20 years, the improvement of knowledge on the pathogenesis of the disease has …
View article: E067 Bimekizumab maintained efficacy responses through 52 weeks in biologic disease-modifying antirheumatic drugnaïve patients with psoriatic arthritis who were responders at week 16: results from BE OPTIMAL, a phase 3, activereference study
E067 Bimekizumab maintained efficacy responses through 52 weeks in biologic disease-modifying antirheumatic drugnaïve patients with psoriatic arthritis who were responders at week 16: results from BE OPTIMAL, a phase 3, activereference study Open
Background/Aims Given the chronic nature of psoriatic arthritis (PsA), sustaining high levels of disease control with treatment is important. Assessing maintenance of response in patients that achieve treatment targets is of interest as lo…
View article: E069 Bimekizumab maintained efficacy responses through 52 weeks in patients with psoriatic arthritis and inadequate response or intolerance to tumour necrosis factor inhibitors who were responders at week 16: results from a phase 3, randomised study
E069 Bimekizumab maintained efficacy responses through 52 weeks in patients with psoriatic arthritis and inadequate response or intolerance to tumour necrosis factor inhibitors who were responders at week 16: results from a phase 3, randomised study Open
Background/Aims Psoriatic arthritis (PsA) is a chronic disease affecting multiple domains; however, patients can experience loss of response with long-term therapy. Therefore, maintaining long-term treatment responses is important. Bimekiz…
View article: Retention rate of biologic and targeted synthetic anti-rheumatic drugs in elderly rheumatoid arthritis patients: data from GISEA registry
Retention rate of biologic and targeted synthetic anti-rheumatic drugs in elderly rheumatoid arthritis patients: data from GISEA registry Open
Objectives An increased number of elderly individuals affected by rheumatoid arthritis (RA) has been reported, including both patients with RA onset in advanced age and patients aged with the disease. In this registry-based study, we aimed…
View article: Recording of non-musculoskeletal manifestations, comorbidities and safety outcomes in European spondyloarthritis registries: a survey
Recording of non-musculoskeletal manifestations, comorbidities and safety outcomes in European spondyloarthritis registries: a survey Open
Objectives Real-world evidence is needed to inform treatment strategies for patients with PsA and axial SpA (axSpA) who have non-musculoskeletal manifestations (NMMs), various risk factors and comorbidities. International collaboration is …
View article: Effect of neridronate on axial involvement in patients with spondyloarthritis when biologics are not possible. Results of a monocentric study
Effect of neridronate on axial involvement in patients with spondyloarthritis when biologics are not possible. Results of a monocentric study Open
Introduction This study aims to examine the potential effectiveness of intravenous neridronate (IVNer) on axial involvement in patients with spondyloarthritis (SpA) refractory to non-steroidal anti-inflammatory drugs (NSAIDs) but not eligi…
View article: The impact of EMA recommendations on the real-life use of Janus kinases inhibitors for rheumatoid arthritis: the Expanded Risk Score in RA as a tool to quantify the risk of cardiovascular events
The impact of EMA recommendations on the real-life use of Janus kinases inhibitors for rheumatoid arthritis: the Expanded Risk Score in RA as a tool to quantify the risk of cardiovascular events Open
Objective To evaluate in patients with rheumatoid arthritis (RA) the impact of EMA recommendations on the real-life prescription of JAK inhibitors (JAKis) and the use of the Expanded Risk Score in RA (ERS-RA) to quantify the risk of major …
View article: Retention rate of tumor necrosis factor inhibitors, anti-interleukin 17, and anti-interleukin 12/23 drugs in a single-center cohort of psoriatic arthritis patients
Retention rate of tumor necrosis factor inhibitors, anti-interleukin 17, and anti-interleukin 12/23 drugs in a single-center cohort of psoriatic arthritis patients Open
The objective of this study was to evaluate biological disease-modifying anti-rheumatic drugs (bDMARDs) survival in several therapy courses of patients affected by psoriatic arthritis (PsA) and to compare tumor necrosis factor inhibitors (…
View article: AB0989 ARE OSTEOPOROSIS AND FRACTURES NEGLECTED ISSUES IN AXIAL SPONDYLOARTHRITIS? DATA FROM A CROSS-SECTIONAL MONOCENTRIC STUDY
AB0989 ARE OSTEOPOROSIS AND FRACTURES NEGLECTED ISSUES IN AXIAL SPONDYLOARTHRITIS? DATA FROM A CROSS-SECTIONAL MONOCENTRIC STUDY Open
View article: POS1534 BIMEKIZUMAB MAINTAINED EFFICACY RESPONSES THROUGH 52 WEEKS IN BIOLOGIC DISEASE-MODIFYING ANTIRHEUMATIC DRUG-NAÏVE PATIENTS WITH PSORIATIC ARTHRITIS WHO WERE RESPONDERS AT WEEK 16: RESULTS FROM BE OPTIMAL, A PHASE 3, ACTIVE-REFERENCE STUDY
POS1534 BIMEKIZUMAB MAINTAINED EFFICACY RESPONSES THROUGH 52 WEEKS IN BIOLOGIC DISEASE-MODIFYING ANTIRHEUMATIC DRUG-NAÏVE PATIENTS WITH PSORIATIC ARTHRITIS WHO WERE RESPONDERS AT WEEK 16: RESULTS FROM BE OPTIMAL, A PHASE 3, ACTIVE-REFERENCE STUDY Open
View article: AB0463 THE IMPACT OF PHARMACOVIGILANCE RISK ASSESSMENT COMMITTEE (PRAC) RECOMMENDATIONS ON THE REAL-LIFE USE OF JANUS KINASES INHIBITORS FOR RHEUMATOID ARTHRITIS
AB0463 THE IMPACT OF PHARMACOVIGILANCE RISK ASSESSMENT COMMITTEE (PRAC) RECOMMENDATIONS ON THE REAL-LIFE USE OF JANUS KINASES INHIBITORS FOR RHEUMATOID ARTHRITIS Open
View article: POS0024 RETENTION RATE OF TNF INHIBITORS (TNFI), ANTI-IL17, AND ANTI-IL12/23 DRUGS IN A SINGLE-CENTER COHORT OF PSORIATIC ARTHRITIS PATIENTS
POS0024 RETENTION RATE OF TNF INHIBITORS (TNFI), ANTI-IL17, AND ANTI-IL12/23 DRUGS IN A SINGLE-CENTER COHORT OF PSORIATIC ARTHRITIS PATIENTS Open
View article: POS0233 DISEASE COURSE AND PREDICTORS FOR ACHIEVING 6-MONTH MINIMAL DISEASE ACTIVITY IN PATIENTS WITH EARLY PSORIATIC ARTHRITIS FROM THE ITALIAN PROSPECTIVE SIRENA STUDY
POS0233 DISEASE COURSE AND PREDICTORS FOR ACHIEVING 6-MONTH MINIMAL DISEASE ACTIVITY IN PATIENTS WITH EARLY PSORIATIC ARTHRITIS FROM THE ITALIAN PROSPECTIVE SIRENA STUDY Open
View article: AB1138 DIFFICULT-TO-TREAT PSORIATIC ARTHRITIS: ANALYSIS OF A SINGLE-CENTER COHORT FROM NORTHERN ITALY
AB1138 DIFFICULT-TO-TREAT PSORIATIC ARTHRITIS: ANALYSIS OF A SINGLE-CENTER COHORT FROM NORTHERN ITALY Open